TG THERAPEUTICS INC. - COMMON STOCK

35,07

22-ноября-24 15:44:58

15 мин. задержка

Акции

+0,52

+1,51%

Сегодняшний диапазон

33,71 - 35,32

ISIN

N/A

Источник

NASDAQ

TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

06 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

05 авг 2024 06:30:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

17 июл 2024 08:58:20 Источник NetDania Notify
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

07 июн 2024 06:50:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

03 июн 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

31 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

28 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

01 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

30 апр 2024 15:55:29 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

18 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

18 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

15 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

08 мар 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

01 мар 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

28 фев 2024 06:00:01 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

27 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

26 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

23 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

20 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

10 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.